Contractors File Suit Against New York MTA’s New Debarment Regime
Client Alert | 1 min read | 12.05.19
On November 25, 2019, the Alliance For Fair and Equitable Contracting Today, Inc. (AFFECT) sued the Metropolitan Transportation Authority (MTA) in the Southern District of New York to enjoin and declare unconstitutional a new contractor debarment regime implemented by the New York legislature and the MTA on November 6, 2019. This new debarment regime—upon which there was no opportunity for public comment—requires, among other things, the MTA to automatically debar a contractor that fails to complete a project by a contractual deadline or claims costs in excess of a project budget, without providing the MTA discretion to even consider mitigating facts or circumstances that might impact project deadlines or budgets. This applies both prospectively to new contracts and retroactively to all contracts already in existence, including those entered into before April 2019, when the New York legislature passed the new Debarment Statute requiring the implementation of this regime. The regime also applies to a targeted contractor’s (1) “parent(s), subsidiaries and affiliates”; (2) “directors, officers, principals, managerial employees and any person or entity with a 10% or more interest in a contractor”; and (3) “any joint venture (including its individual members) and any other form of partnership (including its individual members) that includes a contractor or a contractor’s parent(s), subsidiaries, or affiliates of a contractor.” AFFECT’s lawsuit alleges this regime violates the U.S. Constitution’s Contract Clause, Supremacy Clause, Dormant Commerce Clause, procedural and substantive Due Process requirements, and the First Amendment. If not successfully enjoined, this may encourage the New York State Legislature to enact similar laws and require other state agencies to establish similar debarment regimes, and may even motivate other states to do the same.
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today